Abstract
NY-ESO-1 specific humoral responses are frequently observed in patients with various types of NY-ESO-1 antigen expressing tumors. In a large proportion of NY-ESO-1 antibody-positive patients of NY-ESO-1-specific CD8 T-cells can also be detected suggesting that monitoring of the NY-ESO-1 specific humoral immune response may be a relevant and more practical surrogate for estimating the overall immune response against NY-ESO-1 in clinical vaccine studies. We have immunized 9 cancer patients with full length NY-ESO-1 protein formulated with cholesterol-bearing hydrophobized pullulan (CHP-NY-ESO-1) and investigated the humoral immune responses against NY-ESO-1. Seven patients were NY-ESO-1 antibody-negative and 2 patients were positive prior to vaccination. Vaccination with CHP-NY-ESO-1 resulted in the induction or increase of NY-ESO-1 antibody responses in all 9 patients immunized. Epitope analysis revealed 5 regions in the NY-ESO-1 protein molecule that were recognized by antibodies induced after vaccination. The 5 regions were also recognized by antibodies present in nonvaccinated, NY-ESO-1 antibody-positive cancer patients. A peptide spanning amino acids 91-108 was recognized in 6 out of 9 vaccinated patients and in 8 out of 9 nonvaccinated, sero-positive patients, being the most dominant antigenic epitope in NY-ESO-1 for antibody recognition in cancer patients. In conclusion, we showed that CHP-NY-ESO-1 protein vaccination had a potent activity for inducing humoral immune responses against NY-ESO-1 antigen in cancer patients. The antigenic epitopes recognized by antibodies in the vaccinated patients were similar to those recognized in cancer patients with spontaneous humoral immunity against NY-ESO-1.
| Original language | English |
|---|---|
| Pages (from-to) | 2178-2184 |
| Number of pages | 7 |
| Journal | International Journal of Cancer |
| Volume | 120 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - May 15 2007 |
Fingerprint
Keywords
- Antibody response
- Cancer vaccine
- CHP
- NY-ESO-1
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. / Kawabata, Ryohei; Wada, Hisashi; Isobe, Midori; Saika, Takashi; Sato, Shuichiro; Uenaka, Akiko; Miyata, Hiroshi; Yasuda, Takushi; Doki, Yuichiro; Noguchi, Yuji; Kumon, Hiromi; Tsuji, Kazuhide; Iwatsuki, Keiji; Shiku, Hiroshi; Ritter, Gerd; Murphy, Roger; Hoffman, Eric; Old, Lloyd J.; Monden, Morito; Nakayama, Eiichi.
In: International Journal of Cancer, Vol. 120, No. 10, 15.05.2007, p. 2178-2184.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients
AU - Kawabata, Ryohei
AU - Wada, Hisashi
AU - Isobe, Midori
AU - Saika, Takashi
AU - Sato, Shuichiro
AU - Uenaka, Akiko
AU - Miyata, Hiroshi
AU - Yasuda, Takushi
AU - Doki, Yuichiro
AU - Noguchi, Yuji
AU - Kumon, Hiromi
AU - Tsuji, Kazuhide
AU - Iwatsuki, Keiji
AU - Shiku, Hiroshi
AU - Ritter, Gerd
AU - Murphy, Roger
AU - Hoffman, Eric
AU - Old, Lloyd J.
AU - Monden, Morito
AU - Nakayama, Eiichi
PY - 2007/5/15
Y1 - 2007/5/15
N2 - NY-ESO-1 specific humoral responses are frequently observed in patients with various types of NY-ESO-1 antigen expressing tumors. In a large proportion of NY-ESO-1 antibody-positive patients of NY-ESO-1-specific CD8 T-cells can also be detected suggesting that monitoring of the NY-ESO-1 specific humoral immune response may be a relevant and more practical surrogate for estimating the overall immune response against NY-ESO-1 in clinical vaccine studies. We have immunized 9 cancer patients with full length NY-ESO-1 protein formulated with cholesterol-bearing hydrophobized pullulan (CHP-NY-ESO-1) and investigated the humoral immune responses against NY-ESO-1. Seven patients were NY-ESO-1 antibody-negative and 2 patients were positive prior to vaccination. Vaccination with CHP-NY-ESO-1 resulted in the induction or increase of NY-ESO-1 antibody responses in all 9 patients immunized. Epitope analysis revealed 5 regions in the NY-ESO-1 protein molecule that were recognized by antibodies induced after vaccination. The 5 regions were also recognized by antibodies present in nonvaccinated, NY-ESO-1 antibody-positive cancer patients. A peptide spanning amino acids 91-108 was recognized in 6 out of 9 vaccinated patients and in 8 out of 9 nonvaccinated, sero-positive patients, being the most dominant antigenic epitope in NY-ESO-1 for antibody recognition in cancer patients. In conclusion, we showed that CHP-NY-ESO-1 protein vaccination had a potent activity for inducing humoral immune responses against NY-ESO-1 antigen in cancer patients. The antigenic epitopes recognized by antibodies in the vaccinated patients were similar to those recognized in cancer patients with spontaneous humoral immunity against NY-ESO-1.
AB - NY-ESO-1 specific humoral responses are frequently observed in patients with various types of NY-ESO-1 antigen expressing tumors. In a large proportion of NY-ESO-1 antibody-positive patients of NY-ESO-1-specific CD8 T-cells can also be detected suggesting that monitoring of the NY-ESO-1 specific humoral immune response may be a relevant and more practical surrogate for estimating the overall immune response against NY-ESO-1 in clinical vaccine studies. We have immunized 9 cancer patients with full length NY-ESO-1 protein formulated with cholesterol-bearing hydrophobized pullulan (CHP-NY-ESO-1) and investigated the humoral immune responses against NY-ESO-1. Seven patients were NY-ESO-1 antibody-negative and 2 patients were positive prior to vaccination. Vaccination with CHP-NY-ESO-1 resulted in the induction or increase of NY-ESO-1 antibody responses in all 9 patients immunized. Epitope analysis revealed 5 regions in the NY-ESO-1 protein molecule that were recognized by antibodies induced after vaccination. The 5 regions were also recognized by antibodies present in nonvaccinated, NY-ESO-1 antibody-positive cancer patients. A peptide spanning amino acids 91-108 was recognized in 6 out of 9 vaccinated patients and in 8 out of 9 nonvaccinated, sero-positive patients, being the most dominant antigenic epitope in NY-ESO-1 for antibody recognition in cancer patients. In conclusion, we showed that CHP-NY-ESO-1 protein vaccination had a potent activity for inducing humoral immune responses against NY-ESO-1 antigen in cancer patients. The antigenic epitopes recognized by antibodies in the vaccinated patients were similar to those recognized in cancer patients with spontaneous humoral immunity against NY-ESO-1.
KW - Antibody response
KW - Cancer vaccine
KW - CHP
KW - NY-ESO-1
UR - http://www.scopus.com/inward/record.url?scp=34147101570&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34147101570&partnerID=8YFLogxK
U2 - 10.1002/ijc.22583
DO - 10.1002/ijc.22583
M3 - Article
C2 - 17278093
AN - SCOPUS:34147101570
VL - 120
SP - 2178
EP - 2184
JO - International Journal of Cancer
JF - International Journal of Cancer
SN - 0020-7136
IS - 10
ER -